<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088527</url>
  </required_header>
  <id_info>
    <org_study_id>RAD140-01-001</org_study_id>
    <nct_id>NCT03088527</nct_id>
  </id_info>
  <brief_title>Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer</brief_title>
  <official_title>A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the clinical safety profile, tolerability,
      and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first in humans study that is designed to evaluate the clinical safety profile,
      tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive
      breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of dose-limiting toxicities (DLTs) RAD140 treatment</measure>
    <time_frame>First 28 days of treatment</time_frame>
    <description>Incidence rate of dose-limiting toxicities (DLTs) RAD140 treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events related to study treatment</measure>
    <time_frame>Up to 30 days after end of treatment</time_frame>
    <description>Number of adverse events related to study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number participants with dose interruptions and dose adjustments</measure>
    <time_frame>Up to 30 days after end of treatment</time_frame>
    <description>Number participants with dose interruptions and dose adjustments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1 and 15</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Day 1 and 15</time_frame>
    <description>Time to maximum plasma concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Screening and every 8 weeks for up to 12 months of treatment</time_frame>
    <description>Clinical benefit rate (CBR) or objective response rate (ORR) will be assessed by Investigators per RECIST v1.1 along with time-related efficacy endpoints.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hormone Receptor Positive Malignant Neoplasm of Breast</condition>
  <arm_group>
    <arm_group_label>RAD140 Part A and Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of RAD140.
Part B, Safety Expansion: Once the maximum tolerated dose (MTD) has been identified and/or a recommended dose escalation (RDE) has been determined, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary clinical activity of the recommended dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD140</intervention_name>
    <description>RAD140 will be supplied as formulated drug-in-capsules for oral administration.</description>
    <arm_group_label>RAD140 Part A and Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Progressive metastatic or locally advanced or metastatic breast cancer.

          -  Clinically confirmed as postmenopausal.

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 1 at screening.

        Key Exclusion Criteria:

          -  HER2 positive patients by local laboratory testing.

          -  Triple negative breast cancer.

          -  Any chemotherapy within the 28 days prior to the first dose of study drug.

          -  Any non-chemotherapy anti-cancer drug less than 5 half-lives (30 days for biologics)
             or less than 14 days for small molecule therapeutics, or if half-life is not known.

          -  Tamoxifen and aromatase inhibitors within 14 days prior to the first dose of study
             drug.

          -  Fulvestrant within 30 days prior to first dose of study drug.

          -  Any investigational drug therapy within 5 half-lives of the previous investigational
             study drug or 30 days, whichever is shorter.

          -  Radiation therapy for breast cancer within 2 weeks of dosing and planning to have
             radiation therapy during participation in this study.

          -  Known history of human immunodeficiency virus infection (HIV) or hepatitis C or active
             hepatitis B infection, unless the patient was diagnosed &gt;10 years prior to enrollment
             and no evidence of active liver disease.

          -  Currently taking testosterone, methyltestosterone, oxandrolone (Oxandrin),
             oxymetholone, danazol, fluoxymesterone (Halotestin), or testosterone-like agents.

          -  Untreated or uncontrolled brain metastasis.

          -  Diagnosed with or treated for cancer within the previous 2 years, other than breast
             cancer or non-melanoma carcinoma of the skin.

          -  Pregnant and nursing females.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Director, Clinical Operations</last_name>
    <role>Study Director</role>
    <affiliation>Radius</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center Protocol Office</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

